---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-23-000004"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T08:38:23.885187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q4 revenue -3% to $708.7M, adj. EPS $1.77; FY23 guidance $7.25-$7.40, $1B buyback

## Summary
- Q4 net sales $708.7M (-3.0% reported, +2.6% organic); reported EPS $1.36, adjusted EPS $1.77.
- Full-year 2022 net sales $2.887B (+2.0% reported, +7.7% organic); reported EPS $7.73, adjusted EPS $8.58.
- FY 2023 guidance: net sales $2.935-2.960B, adj. EPS $7.25-7.40; COVID sales ~$85M (vs $388M in 2022).
- Board approved new $1.0B share repurchase program, no expiration; prior program expired Dec 31, 2022.
- Operating cash flow $724.0M (+24%); free cash flow $439.4M (+32.9%); capex $284.6M.

## SEC filing metadata
- accession: 0000105770-23-000004
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/wst-20230215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-23-000004
- JSON: https://secwatch.observer/filing/0000105770-23-000004.json
- Plain text: https://secwatch.observer/filing/0000105770-23-000004.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported full-year 2023 results: revenue $2.935 billion to $2.960 billion, EPS $7.25 to $7.40. Guidance initiated.
  - Period: full-year 2023
  - Revenue: $2.935 billion to $2.960 billion
  - EPS: $7.25 to $7.40
  - Guidance: initiated
  - Result: guidance update
  source text: The Company is introducing full-year 2023 financial guidance of net sales in a range of $2.935 billion to $2.960 billion and adjusted-diluted EPS in a range of $7.25 to $7.40.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2022 results: revenue $708.7 million. Guidance initiated.
  - Period: the fourth-quarter and full-year 2022
  - Revenue: $708.7 million
  - Guidance: initiated
  - Result: reported results
  source text: West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2022 and introduced full-year 2023 financial guidance. Fourth-Quarter and Full-Year 2022 Summary (comparisons to prior-year period) • Fourth-quarter 2022 net sales of $708.7 million declined 3.0%; organic net sales growth was 2.6%
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.